The proprietor of Foresite Capital posits that he founded the entity with the objective of providing healthcare entrepreneurs and companies with adequate resources, information and connections to enable them to enhance their operations in the industry. Jim contends that the industry is capital-intensive. This way, lack of adequate capital limits the number of people who can venture into the healthcare industry.
Jim contends that even though he has been focusing on the investment and business side of healthcare, he considers himself as an academician at heart. Tananbaum posits that his love of learning has driven him to find the brightest and best solutions that science can offer. He adds that his passion for developing viable solutions coupled with unwavering commitment and persistence has enabled him to continue enhancing the firm’ growth. He has also played a pivotal role in expanding Foresite Capital’s portfolio.
Tananbaum spends most of his working days in his company brainstorming on various ideas. He also interacts with his team and friends. However, he prioritizes his family. Jim endeavors to have dinner with them every evening. Tananbaum remains optimistic that in the near future, it will be possible for medical practitioners to diagnose diseases and treat them by sequencing patient’s saliva, tissue and blood. It is for this reason that the executive has endeavored to support innovation that seeks to enhance scientific discoveries.
Foresite has a large portfolio of more than 70 companies. According to pelotontherapeutics.com, most of these entities offer different services in the vast healthcare industry, including genomic sequencing, biopharmaceuticals, diagnostics and medical services. Jim continues to inspire many entrepreneurs to venture into the industry and use technology to develop innovative products and services.
About Jim Tananbaum
Jim is a renowned entrepreneur who is credited for incorporating Theravance and GelTex Pharmaceuticals. The latter made headlines when it introduced two successful drugs into the market. Owing to the success of the company, it was acquired in 1998 for a consideration of $1.6 billion. In addition from Inc42, Tananbaum is the brain behind the success of Prospect Venture Partners II and III.
The alumnus of the prestigious Massachusetts Institute of Technology (MIT) was a partner at Sierra Ventures. Moreover, he is credited for enhancing the success of Healtheon, Amira Pharmaceuticals, Jazz Pharmaceuticals and Amerigroup.